We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+33.16%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$745M
AUM Growth
+$34.8M
Cap. Flow
-$59.1M
Cap. Flow %
-7.93%
Top 10 Hldgs %
91.04%
Holding
31
New
2
Increased
8
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
LCI
Lannett Company, Inc.
LCI
+$54M
2
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$51.2M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$4.12M
4
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
+$2.78M
5
OFIX icon
Orthofix Medical
OFIX
+$2.35M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$38.5M
2
CSII
Cardiovascular Systems, Inc.
CSII
+$36.9M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$20.6M
4
INSY
Insys Therapeutics, Inc.
INSY
+$19.1M
5
EPRS
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.18%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSTG
26
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-449,325
Closed -$7.19M
CSII
27
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-2,326,748
Closed -$36.9M
CLVS
28
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-45,183
Closed -$4.16M
EVFM
29
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
– –
-1,359
Closed -$987K
IMPR
30
DELISTED
IMPRIVATA, INC COM
IMPR
– –
-206,448
Closed -$3.67M
EPRS
31
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
– –
-2,324,669
Closed -$10.3M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Consonance Capital Management held 31 positions worth $745M, up 4.9% from $711M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Consonance Capital Management withdrew a net $59.1M in Q4 2015, closing 9 positions and reducing 11 holdings. Its most notable exit was Cardiovascular Systems, Inc., an estimated $36.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 85% a quarter earlier, followed by Technology.

Against the trend, Consonance Capital Management opened a new position in Lannett Company, Inc. worth $52.8M.

  • Consonance Capital Management's largest Q4 2015 buy was Lannett Company, Inc.: 329,175 shares worth $52.8M.
  • Consonance Capital Management added most to Eagle Pharmaceuticals, Inc. in Q4 2015, an estimated $4.12M increase.
  • Consonance Capital Management's biggest Q4 2015 reduction was AbbVie, cutting an estimated $38.5M.
  • Consonance Capital Management fully exited Cardiovascular Systems, Inc. in Q4 2015, selling an estimated $36.9M.
  • Consonance Capital Management's ten largest holdings make up 91% of its $745M portfolio in Q4 2015.
  • Consonance Capital Management opened 2 new positions and closed 9 in Q4 2015.
  • Consonance Capital Management's portfolio value rose 4.9% quarter-over-quarter to $745M.

Based on Consonance Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.